You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy
Free
  1. Shu Su1,
  2. Baorui Liu1 and
  3. Zhengyun Zou2
  1. Aff1 grid.41156.37000000012314964XThe Comprehensive Cancer Centre of Drum Tower HospitalMedical School of Nanjing University Nanjing China
  2. Aff2 grid.41156.37000000012314964XThe Comprehensive Cancer Center of Drum-Tower HospitalMedical School of Nanjing University & Clinical Cancer Institute of Nanjing University Nanjing China

https://doi.org/10.1186/2051-1426-3-S2-P53

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Strategies that enhance the function of T cells are critical for immunotherapy.

    Methods

    Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1.

    Results

    We showed that the gene knockout of PD-1 by electroporation of plasmids encoding sgRNA and Cas9 was technically feasible. The disruption of PD-1 resulted in significant reduction of PD-1 expression but didn't affect the viability of primary human T cells. Cellular immune response of the gene modified T cells was characterized by up-regulated IFN-γ production and enhanced cytotoxicity.

    Conclusions

    These results suggest that we have established an approach for efficient checkpoint inhibitor disruption, providing a new strategy for targeting checkpoint inhibitors to improve the efficacy of T cell based adoptive therapies.

    Figure
    Figure
    Figure

    Acknowledgments

    The authors thank the entire Huang Lab and Liu Lab for their support and advice. This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81172281, 81000980, 81220108023, 81172094).

    References

    1. 1.
      1. Topalian SL,
      2. Hodi S,
      3. Brahmer JR,
      4. Gettinger SN,
      5. Smith DC,
      6. McDermott DF, et al
      . Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. pmcid:3544539 doi:10.1056/NEJMoa1200690
      OpenUrlCrossRefPubMedWeb of Science
    2. 2.
      1. Pen JJ,
      2. Keersmaecker BD,
      3. Heirman C,
      4. Corthals J,
      5. Liechtenstein T,
      6. Escors D, et al
      . Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014;21:3262–271. doi:10.1038/gt.2013.80
      OpenUrlCrossRefPubMed
    3. 3.
      1. Lloyd A,
      2. Vickery ON,
      3. Laugel B
      . Beyond the antigen receptor: editing the genome of T cells for cancer adoptive cellular therapies. Front Immunol. 2013;4:221. pmcid:3733021 doi:10.3389/fimmu.2013.00221
      OpenUrlCrossRefPubMed
    4. 4.
      1. Li W,
      2. Teng F,
      3. Li T,
      4. Zhou Q
      . Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol. 2013;31:8684–686. doi:10.1038/nbt.2652
      OpenUrlCrossRefPubMed
    5. 5.
      1. Shen B,
      2. Zhang J,
      3. Wu H,
      4. Wang J,
      5. Ma K,
      6. Li Z, et al
      . Generation of gene- modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013;23:720–723. pmcid:3641603 doi:10.1038/cr.2013.46
      OpenUrlCrossRefPubMedWeb of Science
    6. 6.
      1. Niu Y,
      2. Shen B,
      3. Cui Y,
      4. Chen Y,
      5. Wang J,
      6. Wang L, et al
      . Generation of gene-modified Cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014;156:41–8. doi:10.1016/j.cell.2014.01.027
      OpenUrl
    7. 7.
      1. Shen B,
      2. Zhang W,
      3. Zhang J,
      4. Zhou J,
      5. Wang J,
      6. Chen L, et al
      . Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014;11:4399–402. doi:10.1038/nmeth.2857
      OpenUrlCrossRefPubMedWeb of Science
    8. 8.
      1. Topalian SL,
      2. Hodi FS,
      3. Brahmer JR,
      4. Gettinger SN,
      5. Smith DC,
      6. McDermott DF, et al
      . Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2014;366:262443–2454. doi:10.1056/NEJMoa1200690
      OpenUrl
    9. 9.
      1. Iwamura K,
      2. Kato T,
      3. Miyahara Y,
      4. Naota H,
      5. Mineno J,
      6. Ikeda H, et al
      . siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T cell effector functions. Gene Therapy. 2012;19:10959–966. doi:10.1038/gt.2011.185
      OpenUrlCrossRefPubMed
    10. 10.
      1. Chicaybam L,
      2. Sodre AL,
      3. Curzio BA,
      4. Bonamino MH
      . An efficient low cost method for gene transfer to T lymphocytes. PLOS One. 2013;8:e60298. pmcid:3608570 doi:10.1371/journal.pone.0060298
      OpenUrlCrossRefPubMed